Reuters reports that on the launch of Verve Therapeutics, a biotech focused on using gene editing to treat cardiovascular disease.
Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
The partnership will allow people to see their genetic risk with other health data that Seqster pulls from electronic health records and wearables.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.
Researchers compared findings from genome-wide association studies for 62 traits or conditions with genes implicated in 20 Mendelian disorder types, uncovering new ties.
The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of the test as an LDT.
In Nature this week: statistical method for overcoming case-control imbalance issues, and more.
Genome-wide polygenic risk scores highlight those at risk of coronary artery disease, atrial fibrillation, type 2 diabetes, IBD, and breast cancer.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.